The FDA has approved the 32 mg tablet strength of Mallinckrodt’s EXALGO® (hydromorphone HCI) Extended-Release Tablets for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time. The FDA approved the 8, 12 and 16 mg tablets of EXALGO in March 2010 and the Supplemental New Drug Application (sNDA) for the 32 mg tablet was submitted earlier this year. The EXALGO 32 mg tablet strength will be available in the next few weeks.
EXALGO is dosed just once per day and steady-state is reached in 3-4 days. It is a fairly expensive long-acting opioid, with a price per day in the $15-30 range (depending on tablet strength).
All EXALGO dosage strengths, including the new 32 mg tablet, are subject to the recently approved Risk Evaluation and Mitigation Strategy (REMS) program for all long-acting and extended-release opioids. Currently, Mallinckrodt maintains the EXALGO REMS program web site at www.exalgorems.com.
The strong opioid, hydromorphone, is once again available as an extended release tablet providing long-acting opioid effects. The FDA recently approved Exalgo which is a once-a-day long-acting tablet providing hydromorphone in 8mg, 12mg, and 16mg strengths. It is indicated for the management of moderate to severe pain in opioid tolerant patients (such as hospice patients) who require continuous, around the clock opioid analgesia for an extended period of time. It is not intended for PRN use. Short-acting hydromorphone (Dilaudid) tablets, oral solution, or suppositories may be used on a PRN basis.
Patients must be able to swallow whole tablets since Exalgo cannot be crushed, chewed, or dissolved. It may be taken with or without food. Another long-acting hydromorphone product, Pallidone, was available for a brief time in the U.S. several years ago, but was pulled from the market in 2005 due to fatalities encountered when the drug was taken with alcohol. It was determined that alcohol hampered the extended release mechanism of Pallidone, resulting in dose dumping and subsequent toxic blood levels of the drug. An in vivo study examined the effect of alcohol on the bioavailability of a single dose of 16mg Exalgo in healthy, fasted or fed volunteers. The results showed that changes in the hydromorphone blood levels (mean AUC0.oc) were not statistically significant after co-administration with 40% alcohol. Recent advances in extended release tablet technology apparently have conferred better protection against alcohol interference with the drug release, however, patients are still advised to avoid alcohol while taking this drug.
The price will be in the range of $15.00 per tablet for the 12mg strength.
For More Information: http://exalgo.com/
|I am on exalgo now 4 the fourth day. I think its gona be great.my mom is on hospice an im gona ask about it 4 her if my results keep doin the same.
Posted 6/2/2012 05:30:19 PM
|First 10||<<Previous 10||Next 10 >>||Last 10|
Education Resources and Support for Hospices
Stay up-to-date on the latest hospice pharmacy benefits management information and tools with a variety of education resources and support at no extra charge. We offer presentations live at your facility, over the Internet or viateleconference, online service education programs, customized courses, and courses accredited for nursing continuing education credit.
Our palliative care experts provide clinical consulting on important medication management and care decisions. Our non-dispensing pharmacists provide focused attention and unbiased advice.
Why Use A PBM?
Contracting with multiple pharmacies, doing all the reporting, trying to stay current with medical practices and stay compliant while keeping costs down? There’s an easier and more effective way.